Hussman Strategic Advisors Inc. Boosts Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

Hussman Strategic Advisors Inc. lifted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 50.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,600 shares of the biotechnology company's stock after acquiring an additional 4,200 shares during the quarter. United Therapeutics accounts for about 0.9% of Hussman Strategic Advisors Inc.'s portfolio, making the stock its 12th largest position. Hussman Strategic Advisors Inc.'s holdings in United Therapeutics were worth $3,884,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in UTHR. Parallel Advisors LLC lifted its position in United Therapeutics by 2.8% in the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock valued at $385,000 after purchasing an additional 30 shares during the period. Signaturefd LLC lifted its position in United Therapeutics by 4.7% in the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock valued at $234,000 after purchasing an additional 30 shares during the period. Anchor Investment Management LLC lifted its position in United Therapeutics by 12.0% in the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 30 shares during the period. Hohimer Wealth Management LLC lifted its position in United Therapeutics by 0.3% in the first quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock valued at $3,900,000 after purchasing an additional 37 shares during the period. Finally, Florida Financial Advisors LLC lifted its position in shares of United Therapeutics by 6.2% during the 4th quarter. Florida Financial Advisors LLC now owns 822 shares of the biotechnology company's stock valued at $290,000 after acquiring an additional 48 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Transactions at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $279.96, for a total value of $3,079,560.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares in the company, valued at $10,297,208.76. This trade represents a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO James Edgemond sold 12,000 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the sale, the chief financial officer owned 8,118 shares of the company's stock, valued at $2,641,353.66. The trade was a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 73,681 shares of company stock worth $22,140,089 in the last quarter. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Performance

Shares of United Therapeutics stock traded down $2.43 during trading on Friday, reaching $294.90. The company had a trading volume of 24,685 shares, compared to its average volume of 441,255. The company has a market cap of $13.30 billion, a price-to-earnings ratio of 11.77, a price-to-earnings-growth ratio of 6.52 and a beta of 0.53. The firm's fifty day moving average is $300.61 and its 200-day moving average is $318.55. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The company's revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $6.17 EPS. On average, research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analysts Set New Price Targets

UTHR has been the subject of several research reports. HC Wainwright restated a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Monday, May 5th. Bank of America cut their price objective on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research report on Wednesday, June 11th. Wells Fargo & Company restated an "equal weight" rating and set a $314.00 price objective (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. UBS Group cut their price objective on United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a research report on Monday, June 30th. Finally, Morgan Stanley cut their price objective on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $383.08.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.